TW203558B - Antifungal composition for external application - Google Patents

Antifungal composition for external application Download PDF

Info

Publication number
TW203558B
TW203558B TW81105209A TW81105209A TW203558B TW 203558 B TW203558 B TW 203558B TW 81105209 A TW81105209 A TW 81105209A TW 81105209 A TW81105209 A TW 81105209A TW 203558 B TW203558 B TW 203558B
Authority
TW
Taiwan
Prior art keywords
alcohol
item
pharmaceutical composition
composition
group
Prior art date
Application number
TW81105209A
Other languages
Chinese (zh)
Inventor
Noda Etsunosuke
Yamada Masayuki
Sakae Satoshi
Chayahara Yuji
Original Assignee
Takeda Pharm Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharm Industry Co Ltd filed Critical Takeda Pharm Industry Co Ltd
Application granted granted Critical
Publication of TW203558B publication Critical patent/TW203558B/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This antifungal composition for external application contains 0.2 to 5 w/v% of an imidazole drug, 2 to 30 w/v% of a higher fatty acid ester which is liquid at ordinary temperature and at least 45 w/v% of a lower alcohol as essential ingredients. The antifungal composition of the present invention is highly absorbable and capable of delivering the active substance far into the horny layer of the skin, with the additional advantage of safety and ease of use. Therefore, the composition exhibits excellent efficacy in mycotic skin diseases such as trichophytosis, tinea vesicolor and candidiasis.

Description

203558 Λ fi Π 6 五、發明説明(3) 經濟部屮央櫺準局ex工消件合作社印製 抗力的 。受致。 有抗氨 幾此外苯蔻活收亦 用動強 病忍會法 含用如 般因等三豆的吸受 外透增 菌難不療 的外物 一 。此代肉良低感 的滲生 珠很常治 。菌之藥 ,劑為氣的優的用 分和産 念癢通效法癖病唑 物溶作的 V。 現層使 成收以 及瘙其有療髮疾眯 藥受。% 積表質其 性吸, 癣之為有治抗等的 菌接成積體菌角, 活的層 斑致因沒物是此群 真可製體«/真對且 為良質 花導 ,為藥別抗菌 抗上式I/種因而ns 物優角 、病而認的持為球 。等學形 9 各 ,。 藥有之 癬虜然 ,效 ,用念物物藥膏 la6抗時意 唑具膚S-皮。然有性施抗藥合他軟括 於虜滿 咪物皮 為性避當正活已可擇化其或包Z,對皮盡 有成入 病菌躲為真菌劑至選唑於酊劑^物於不 含組深 疾真向視種真製甚先眯溶之製 % 成用果 。 種之 , 性的傾病 一抗之效優和撤醇知1¾組施效感 ) 積 一明送 菌人均疾出強 e 強為退輕乙已 — 用際療腻 t 體 於發輸 真擊人此發具 a -成癣只於種 / 外實治粘 關本質 要襲的將開 ,ft近已發也溶一量等們其有 傜 。物 主能遭人未前na晚唑如且以有重此它 ,上 : 明物性 :之均週病尚之01。咪 ,水物 ,30。當力虜 赌發成活 景廉地人多 ,此(t劑甲而於藥物 、酯是能皮 範本組保 。背皮何病許上在退試苯然溶等成唑丙但透 , 明菌確效明 時且 ,實 癖菌三 不此組咪異 ,滲佳 發真學療發 何 ,死事 發真代 乎,用甲酸性及不 (請先閲讀背而之注意事項洱塡寫本頁) 本紙張尺度逍用中B a家榣準(CNS) T4規格(2)0x297公;«:) 3 81. 7. 20,000¾ (II) Λ 6 Η 6 203558 五、發明説明(4) 在此之前的許多研究,藉由增加溶解度來增進療效及 此等眯唑藥物的使用品質。例如,日本專利公開公報第 17327/1980號,第 119023/1979號,第 17326/1980號及第 17325/1980號掲示水性乙醇為基質的外用溶液及包含氛代 三苯甲眯唑及克羅他米通的藥霜。含有克羅他米通的製劑 ,在氯代三苯甲眯唑的溶解度上十分優異,但有效物質的 滲透性則通常會犧牲,故在治療效果的立場上,並不建議 克羅他米通的添加。也有許多其他製劑可增進氣代三苯甲 咪唑的溶解度,但沒有一種能證明在皮虜滲透及使用感覺 上,充分令人谋意(例如日本專利公開公報第120516/1982 號,第 209213/1982號,第 61518/1985號,第 228412/1985 (請先閲請背而之注意事項再填寫木頁) 第 及 號 ο 號 唑的 咪虜 甲皮 苯到 三質 代物 氛性 及活 退送 癣輸 發法 進無 增統 為糸 的劑 目藥 究的 研知 的習 前但 先 , 然度 雖解 溶 的 安 在 Μίι 種 1 有 没 且 而 〇 宜 適 。 不意 並滿 上人 學 令 藥明 而證 因上 , 用 處使 深易 層容 質及 角全 經濟部中央橾準局只工消费合作杜印製 力性 動全 透安 滲度 及高 收具 吸且 強 , 增處 有深 具 層 種質 1 角 供虜 提皮 於至 在質 的物 目效 的有 明送 發運 本以 學 物 成 組 0 宾 抗 用 外 之 覺 感 用 : fee nE 良 概 改明 及發 高與 與收 物吸 藥的 唑物 眯藥 當該 現 , 發時 並配 究調 研例 展比 擴定 事預 從以 人酵 明级 發低 之及 明酯 發酸 本肪 脂 级 現 發 述0. 上含 於包 基種 ΒΡ_ 明供 發提 本明 〇 發 加本 增 , 著此 顙因 散 擴 至 積 發 — 0 ^ 行量 隹 Μ Mu ϊ 5 眯 的 81. 7. 20,000¾ (II) 本紙張尺度ϋ用中国Η家«毕(CNS) Τ4規格(2丨0>C297公釐) Λ 6 Π 6 203558 五、發明説明(5) (請先閲讀背而之注意事項#塥筠木頁) 唑藥物,2至30重量/體積%之於20¾為液態的高级脂肪酸 酯及至少45重量/體積%的低级醇的外用抗真菌組成物。 發明詳述: 依本發明的外用抗真菌組成物,任何已知只輕撤可溶 的習知抗真菌眯唑藥物,可便利地添加。此眯唑藥物包括 具有一或二或更多苯基的咪唑化合物。苯基較好為一或二 或更多鹵原子如氣所取代。例如,此等唑眯藥物如異康唑 、艾康唑、氧康唑、氣代三苯甲咪唑、梭康唑、透康唑、 雙風唑及米康唑,包括其各種塩類的適當組合中之一種或 二種或多種可便利地使用,但氯代三苯甲眯唑待別有用。 此等抗真菌藥物之比例總組成分之為0.2至5重量/體積百 分比(以下縮寫為w/v % ),基於療效及安全的考慮,較好 為 0.5 至 2w/v%。 經濟部屮央標準局员工消费合作社印製 本發明所使用之於20亡(常溫)為液態之高级脂肪酸酷 ,可廣泛選自已知在脂肪酸部分含8至33個磺原子及在醇 部分含2至33個磺原子,且常溫下為液態的已知高级脂肪 酸酯。此等常溫為液態的高级脂肪酸酯為飽和或不飽和之 高级脂肪酸酯,如異辛烯酸十六烷酯、異硬脂酸異丙酯、 異硬脂酸己基癸基酯、硬脂酸丁酯、新癸酸辛基十二基酷 、十六酸異硬脂醛酯、十六酸異丙酯、十四酸異丙酯、十 四酸辛基十二基酯、十四酸丁酯、十四酸己基癸基醋、十 二酸己酯、十八二烯酸異丙酯、十八二烯酸乙酯等,以及 動植物油如傑育拔油Uojoba oil)和液態羊毛脂。待別優 先使用為十四酸異丙酯。此等較高级脂肪酸酯可以二或多 本紙张尺度边用中a國家標準(CNS) Ή規格(2)0x297公龙) 5 81. 7. 20,000¾ (II) 203558 Λ 6 Π 6 經濟部中央標準局A工消费合作社印製 為。可 原醇或 δ 為當 必,後同收 的進造劑二癸 為 例 % 時 磺 丁二佳 類適。述時然相吸 劑增會解十、 比/V虜 。個 、其 醇加力上蓀 。 。缠 試對上溶 、通 之5W皮性14醇以 级添收之噴圍損持 菌分凳等酯米 份Ε1於散 1 丙或 , 低由吸明或週減的 真成感此醇他 成 2 用擴有、,V 及經的發霜 口表物 抗該用 。二羅 組為施虜含1)獨W/酯 ,意本藥瓶外藥 於 ,使用乙克 總佳是皮為 單45酸分滿依成於品致 用態在使聚 、 在更的的類 可為 肪成人全製積産導 種液物量酸醋 脂及目速醇 ί 類少 脂需令完或堆由, 一為成少油烯 變 酸 , ,迅级 I 醇至 。级必之偽液而並時 含溫組僅單乙mu 肪%態其低 级例%高之劑物溶,離虜 包常,好,化 脂/V液及的 低比/V的透試成用發分皮 可於加最酯氣 级OV為性用(2等的OV態滲此組外揮狀於 物其添 ,醇聚 高52下動使醇此類>6液及定種為中晶用 成 ,量此二基 等 2 溫移所乙 。醇 P 為收確一作物結施 組劑過因乙烯 此為常分物 、等级 δ 溫吸可如接成以物 的解若 。聚油 。佳須充成醇醇低 α 常的 ,假直組會成 明溶且損酸 、 }用較酯的組甲丁 αια,劑分 ,當自劑組 發的 ,減二酯 (6使 ,酸質的如異用 中試成何 ,將試於 本受需而十烯 «/](來%肪物明 , 、使Β明菌些如造類菌生 。 ,接必稠單乙 ^合^ 脂性發類醇合 %’ 發真這論製醇真發制此可為粘為化 Μ 組OW级活本醇丙組 ΐ 本抗之無分级抗也抑為上非虜例氣 、 的13高保 的異種W/進例 成低該象到 學收皮實聚 St 五種 2 此確 子 、多55促比 需此 ,現受 藥吸成的基 (請先閲讀背而之注意事項#填寫本頁) 本紙張尺度逍用中Β國家樣準(CNS) ΤΜ規格(210x297公*) 81. 7. 20,000張(II) 203558 Λ 6 Π 6 五、發明説明(7) 經濟部中央標準局κχ工消费合作社印製 酸、多-20加酸二 施應 實獨成 機化 其而聚或 二油或0-施肪乙tt實量 { 之單組 有氧 ,。基膠 苯樹二之 物脂加 § 如的 醇醇可總 的抗 時器烯溶 、利以份 成级添!1將醇 二元醇為 劑、 液容乙的 酯加或成 組高可{£激元 乙多元例。制劑 溶縮羧陷 丙油獨組 的於,卩剌多 聚 。多比量控合 菌壓 、壓 異、單總。成源此 Μ 廉和 及00和的少ΡΗ螯 真於素止 二油可為 製或因殳皮醇 醇56醇分量為種 抗埔維防 酸荷質例 Ρ 分感。 ,二 二 ο 二成盡作各 用充缕種 二薄物比JI成燥現 物乙 丁20乙該好含的 外式基 一 iOJ等 I 己 、些之需乾出合, 3 為些。最包需 為形甲供 、 醇這劑 必的中 化此1,圍這用 ,可必 用的如提 酯荷。解I,,述類例50等因 、範 。使由物所 接劑劑以 桂 物 丙薄等溶丨上醇個、此。 醇之等物 理成備 直製化 , I 較 合 異 1 酯該由由级些 t 加強 二量等合述組製 可沫膠物 二 d 烯。 全低某 W 添增 丙子酵混上之劑 物泡的成 酸醇丙用述完於在元若為 為分糖之於明藥 成以類組 二 酸使J-種源能 。更 例其梨類基發及 組而醇於 癸 bii物於一種可或需示 實,山種 ,本以 之便级加 、-?、合£»當一 ,/5必所 之等、種/V-, 明方低添 醋 Aei混 ,,感和所例 醇S)醇多OW步齡 發用於可 乙 、甲當 ^ 外時腻物收驗 。二01三或11一機 本使溶 , 二 酯酸適 U 此虜油合吸試小乙og丙二 ο 進有。當為可等 酸乙楊之v°皮的化的與量cr為以之 或等 能 ,物 二 二水種W/於酯醇質例盡Ina例或物 酸劑 可且合 (請先閲讀背而之注意事項再塡寫本頁) 本紙張尺度逍用中B國家楳準(CHS) T4規格(210x297公;it) 81. 7. 20,000¾ (I!) 7 203558___iii_ 五、發明説明(8) 凝膠。該組成物可與LPG—同封於容器中,以提供噴霧製 劑。如此獲致的藥學製剤不只在活性物質的吸收上,而且 也在安全及容易使用上優於目前市售的任何抗真菌製劑。 實施例: 下列實施例和試驗例進一步說明本發明。 [實施例1-4] 依表1所示的配方,混合氛代三苯甲眯唑和十四酸異 丙酯,並以變性醇類製造該混合物,以提供100ml的外用 抗真菌組成物。 (請先閲讀背而之注意事項洱填寫本頁) 和 唑 咪 甲 苯 三 代 氨 合 混 方 配 •-- 1/ 3 的 1-示 例旧 較 比 表 依 異 酸 四 混 或 解 溶 10行 om進 10酯 成丙 使異 , 酸 物四 合十 混或 該類 釋醇 稀性 類變 醇以 性唑 變眯 以甲 並苯 , 三 酯代 丙氛 外 另 裝- 訂_ 例 較 比 之 示 所 IX 表 得 獲 此如。i 1 試 OD收 10吸 成1( 使例 , 驗 合試 線. 經濟部中央標準局Α工消费合作社印製 之结法 1^驗驗 例試試 施 實 之 统 糸 單 簡 最 之 成 組 分1-成例 需較 必比 之及 明物Ιο 發成表 本組於 由用示 全外果 完 以 收 吸 -了 ί— 進 物 成 組 用 外 之 Η 的 蘭剤 法溶 用散 使擴 為 作 及 11* m 1X 各 本 樣 値 每 用 利 ο 胞 細 散 擴 定 測 析 層 相 液 效 高 以 液 溶 水 醇 乙 •溶 散 擴 至 膜 散 擴 虜 皮10 部表 腹於 鼠示 老果 過結 穿 〇 動量 移唑 本咪 樣苯 由甲 , 三 間代 之氣 時之 小劑 81. 7. 20,000¾ (II) 本紙張尺度边用中Β國家«毕(CNS)甲4規格(2]0父297公龙) 203558 五、發明説明(9 ) 表1 實施例 比較例 1 2 3 4 1 2 3 氣代三苯甲咪唑(g) 1 1 -1. 1 1 1 1 十四酸異丙酯(g) 5 10 20 30 50 - 83.9 變性醇類(g) 73.3 68.6 59.3 50.0 31.4 78.1 0 平均值土S.D. (WS) 103.7 120.2 90.4 57.9 27.0 28.4 3.2 士 9.0 土 1.9 土 19.1 ±8.7 土 3.4 ±7.7 ±2.0 (請先閲請背而之注意事項洱填寫木頁) 經濟部屮央標準局员工消赀合作社印製 [實施例5 - 8 ] 氣代三甲苯眯唑和十四酸異丙酯在加有聚乙二醇300 或癸二酸二乙酯或未加情況下混合,該混合物以異丙醇稀 釋使成100ml。如此獲得表2所示抗真菌外用組成物。 [比較例4 - 5 ] 混合氣代三甲苯咪唑和十四酸異丙酯,且該混合物以 異丙醇稀釋使成100ml,或氛代三甲苯眯唑以異丙醇溶解 使100ml。如此獲得表2所示比較例組成物。 試驗例2 (吸收試驗) 實施例5-8為含有異丙酵作為低级醇類,且加有聚乙 二醇300或癸二酸二乙酯或未加的外用組成物。利用此等 本紙張尺度逍用中明國家«準(CNS)T4規格(2】0X297公;¢) 81. 7. 20,000張(11) 203558 五、發明説明(I Ο) 組成物及比較 例4-5之 組成物 為樣 本,如 上述 進行一種 收試驗。結果 掲示於表2。 表 2 實施 例 比 較例 5 6 7 8 4 5 氯代三苯甲咪唑(g) 1 1 1 1 1 1 十四酸異丙酯(g) 2 5 10 15 50 聚乙二醇300(g) - 10 - - - - 癸二酸二乙酯(g) - - 20 - - - 異丙醇(g) 76.5 66.3 52.6 65.8 32.9 78.8 平均值土S.D. (Wg) 42.3 92.0 35.3 30.9 10.1 20.1 ±13.3 ±49.3 ±1.4 ±3·2 ±1.0 ±5.9 (請先閲讀背而之注意事項再填寫本頁) 裝. 線. 經濟部中央標準局员工消费合作社印製 [實施例9 - 1 3 ] 依表3所示的配方,混合氛代三苯甲眯唑、十四酸異 丙酯和克羅他米通,且該混合物以變性乙醇稀釋使成100 Bl。如此獲得外用抗真菌組成物。 [比較例6-8] 依表3所示之配方,混合氛代三苯甲眯唑> 十四酸異 丙酯和克羅他米通,且該混合物以變性醇類稀釋使成100 81. 7. 20,000張(II) 本紙ft尺度逍用中a B家«毕(CNS) TM規格(210X297公¢) 203558 五、發明説明(11) ml,或混合氛代三苯甲眯唑和克羅他米通,且該混合物以 變性醇類或十四酸異丙酯溶解或混合,使成1〇〇1|1丨。如此 獲得表3所示比較例組成物。 試驗例3 (吸收試驗) 實施例9-13為除了本發明之必需成分外,尚含克羅他 米通作為溶解劑之組成物。利用此等组成物和實施例6-8 經濟部中央榣準局员工消费合作社印製 (請先閲請背而之注意事項再塡舄本頁) 的組成物,在 表3。 表 3 上述相 同情況下 進行吸 收試 驗。結 果掲 示於 實施 例 fcb 較 例 9 10 11 12 13 6 7 8 氣代三苯甲咪唑(g) 1 1 1 1 1 1 1 1 十四酸異丙酯(g) 5 10 15 20 30 50 - 79.4 克羅他米通(g) 5 5 5 5 5 5 5 5 變性醇類(g) 70.0 65.2 60.6 56.1 46.9 28.2 74.5 0 平均值土 S.D. 110.0 70.1 65.8 52.2 43.5 19.7 19.9 8.0 ±19.8 土 9.7 土 11,0 土 15,6 ±7.5 士 4.5 土 4.8 土 5.6 本紙張尺度逍用中B國家«毕(CNS)T4規格(210X297公*) 11 81. 7. 20,000張(11) Λ 6 I? 6 203558 五、發明説明(12) (請先閲讀背而之注意事項洱填寫本頁) 由表1和表2明顯可見本發明包含此處待定比例的該高 级脂肪酸酯及低级醇類之抗真菌組成物,顯示優良的吸收 動力學。相對的,習知組成物無法顙示充分的吸收能力。 甚至在眯唑藥物與克羅他米通共同諝配的例子中,依本發 明比例的組成物在吸收上顯著較為優良。 [實施例14-17] 依表4所示的配方,氛代三苯甲眯唑、十四酸異丙酯 、克羅他米通、1-薄荷醇及作為局部麻醉藥的利多卡因在 加有單十二酸聚乙二醇酯和/或丙二醇或未加的情況下混 合,且該混合物以變性酒精稀釋使成100ml。如此獲得外 用抗真菌組成物。 [比較例9 ] 以和實施例17相同方式製備外用抗真菌組成物,但是 略去十四酸異丙酯。 實施例1 7 試驗例4 (吸收試驗) 利用實施例14-17之組成物和比較例9和市售製劑A, 經濟部中央櫺準局Μ工消费合作社印製 B和C ,以上述相同條件進行吸收試驗,結果掲示於表4。 本紙張尺度逍用中Β國家樣準(CHS) Τ4規格(210X297公;it) 12 81. 7 , 20,000張(II) Λ 6 Η 6 203558 五、發明説明(13) 表4203558 Λ fi Π 6 V. Description of the invention (3) Printed by the Ministry of Economic Affairs, Ministry of Economic Affairs, Bureau of Industry and Consumer Goods Cooperatives. Suffer. There are anti-ammonia. In addition, benzoate is also used in the dynamic disease tolerance method, including the use of three beans such as the general absorption of external penetration of bacteria. This generation of infiltrating pearls with good sense and low sense is very common. Bacteria medicine, the agent is the best use of qi and the production of pruritus dissolve V. The current layer makes the harvest and pruritus suffer from squinting. % Accumulate surface quality and attract sex, ringworm is treated with resistant bacteria to form integrated fungus angles, live stratum plaques cause nothing to be this group can really make the body «/ true pair and is good quality flower guide, for The drug type is antibacterial and anti-antibiotic I / species, so it is regarded as a ball. 9 different forms, etc. The medicine has the effect of ringworm, and it is effective, and the anti-spot lacquer S-skin is used with the anti-stress la6 of the substance. However, the sexual application of drugs and other drugs is included in the skin of the full body, and it is optional to avoid it when it is live. It can be used as a fungus to the fungus to select the azole and tincture. Excluding the group's deep diseases, the true vision is the first to be smelted first. In short, the effect of sexual anti-disease primary antibody and the withdrawal of alcohol are known to be effective in group 1¾. This hair a- adult ringworm is only open to the essence of the kind / external treatment of sticky bonds, ft has already been released, and it also dissolves in an amount. Owner can be beaten by others and it is important to repeat it, above: Ming physical properties: the average weekly illness is still 01. Mimi, water, 30. When there is a lot of people in the market, this drug is used to protect the skin. The drug is protected by the skin. The back skin and the disease are allowed to be tested for benzodiazepines, etc. When the effect is obvious and obvious, there are three different groups of real addictive bacteria, the osmosis is really good, the death is really real, use formic acid and not (please read the notes on the back of Eryuan first Page) The standard of this paper is for the use of a family standard (CNS) T4 specification (2) 0x297 g; «:) 3 81. 7. 20,000¾ (II) Λ 6 Η 6 203558 V. Description of the invention (4) in Many previous studies have improved the efficacy and the use quality of these azole drugs by increasing the solubility. For example, Japanese Patent Publication No. 17327/1980, No. 119023/1979, No. 17326/1980 and No. 17325/1980 show aqueous solutions based on water-based ethanol and contain benzotriazole and crotazone. The meton cream. The preparation containing crotamiton is excellent in the solubility of chlorotrimetazole, but the permeability of the effective substance is usually sacrificed. Therefore, from the standpoint of the therapeutic effect, crotamiton is not recommended. Addition. There are also many other formulations that can improve the solubility of airborne tribenzimidazole, but none of them can prove to be sufficiently conspicuous in the penetration of the skin and the feeling of use (for example, Japanese Patent Publication No. 120516/1982, No. 209213 / No. 1982, No. 61518/1985, No. 228412/1985 (please read the precautions before filling in the wooden page) No. ο No. azole of Miguel Benzene to the tertiary generation physical properties and live return The ringworm transfusion method is not prior to the study of the study of the drug medicine without the integration of the Shito, but firstly, although the solution is safe, it is suitable for the M1 species. It is not suitable to meet the academic order of the person. Due to its pharmacological evidence, it is useful for making deep-layered textures and corners. The Central Ministry of Economic Affairs of the Ministry of Economic Affairs only works in consumer cooperation to produce strong dynamic permeability, high permeability, and strong absorption. The layered germplasm 1 corner for the skin to the qualitative physical effect of the clear delivery of the book to the study of the group 0 guest resistance to the external sense of use: fee nE good general improvement and development of high and close The azole squinting medicine should be present, Time and research investigation and exhibition ratio expansion is expected to be based on the human fermentation of low-grade fat and the ester of ester fat acid fat level is now described 0. Contained in the package base species Β_ Ming for the issue of the Ming Mingfa plus This increase is due to the expansion of the distribution to the accumulation of-0 ^ line volume Μ Mu ϊ 5 eye of 81. 7. 20,000¾ (II) This paper size ϋ uses the Chinese Η home «Bi (CNS) Τ4 specifications (2丨 0 > C297mm) Λ 6 Π 6 203558 V. Description of the invention (5) (please read the backing notes first # 塥 筠 木 页) azole drug, 2 to 30% weight / volume of 20¾ is liquid A topical antifungal composition of a higher fatty acid ester and a lower alcohol of at least 45% by weight / volume%. Detailed description of the invention: According to the topical antifungal composition of the present invention, any known antifungal azoles that are only known to be slightly soluble Drugs can be conveniently added. The azole drugs include imidazole compounds having one or two or more phenyl groups. The phenyl group is preferably substituted with one or two or more halogen atoms such as gas. For example, such azole drugs Such as isconazole, iconazole, oxiconazole, aerobic tribenzimidazole, suconazole, pentoconazole, difluconazole Miconazole, including one or two or more of the appropriate combinations of its various classes, can be conveniently used, but chlorinated benzotriazole is not useful. The total composition of these antifungal drugs is 0.2 to 5 weight / volume percentage (hereinafter abbreviated as w / v%), based on the efficacy and safety considerations, preferably 0.5 to 2w / v%. Employee Consumer Cooperative of the Bureau of Standards, Ministry of Economic Affairs Printed in the invention used in the 20 The higher (normal temperature) is a liquid higher fatty acid, which can be widely selected from known higher fatty acid esters known to contain 8 to 33 sulfonic atoms in the fatty acid portion and 2 to 33 sulfonic atoms in the alcohol portion and are liquid at normal temperature . These higher fatty acid esters that are liquid at room temperature are saturated or unsaturated higher fatty acid esters, such as cetyl isooctenoate, isopropyl isostearate, hexyldecyl isostearate, and stearic acid. Butyl acid ester, octyldodecanyl neodecanoate, isostearyl hexadecanoate, isopropyl hexadecanoate, isopropyl myristate, octyl dodecyl myristate, butyl myristate , Hexyldecyl myristate, hexyl dodecanoate, isopropyl octadecenoate, ethyl octadecenoate, etc., as well as animal and vegetable oils such as Uojoba oil and liquid lanolin. I will use isopropyl myristate first. These higher-grade fatty acid esters can be used in two or more paper scales. A National Standard (CNS) Ή Specification (2) 0x297 male dragon) 5 81. 7. 20,000¾ (II) 203558 Λ 6 Π 6 Central Ministry of Economic Affairs Printed by Standard Bureau A Industrial and Consumer Cooperative. But the original alcohol or δ is a must, and then the same recovery agent didecane is used as an example. It is said that the attracting agent will increase the solution, ratio / Vru. One, its alcohol on the sun. . Wrapping test is suitable for dissolving and dissolving 5W skin-type 14 alcohol with a graded spray to contaminate the microbiological stool stool and other ester rice Ε1 in powder 1 C, or low, by the sense of absorption or weekly reduction of this alcohol. Use 2 to expand the surface of the frost mouth, V and meridian against the use. The Erluo group contains 1) W / ester alone, which means that the medicine is used outside the bottle. It is best to use E. g. The class can be fat adult full-scale production of seeding fluid volume of acid esters and eye-speed alcohol. The class of low fat needs to be completed or piled up. One is to make less oil and become acid, and the fast-grade I alcohol. The pseudo-liquid of the grade must be combined with the temperature-containing group at the time, only the content of the single ethyl acetate is higher than that of the lower grade, and the agent is high. The hair split can be used to add the most ester grade OV for sexual use (the second-grade OV state is infiltrated in this group and the wave is added to the material. The alcohol is high 52 and the alcohol is used. The medium crystal is used to measure the amount of the two bases. The alcohol P is used to confirm the application of a crop compound. Ethylene is a common component, and the grade δ temperature absorption can be solved as a connection. Polyester oil. Jiasu must be filled with alcohol and alcohol is low. Often, the pseudo-straight group will become a clear solution and damage the acid.} Use the ester group of methyl butadiene αια, the component, when issued from the agent group, reduce the diester (6 Therefore, if the acid is used in different ways, it will be tested in this case and it will be tested. ^ 合 ^ Fatty Hair Alcohols% 's Reality This theory of alcohol production can be sticky to chemical group OW grade living alcohol group C. The unclassified resistance of this antibody is also suppressed. The 13 high-guaranteed heterogeneous W / into a low case, the elephant to learn and gather together St Five 2 This is correct, more than 55 is needed, and it is now based on the drug absorption (please read the back to the precautions # fill out this page) This paper standard is used in the national standard (CNS) TM specifications (210x297 Public *) 81. 7. 20,000 sheets (II) 203558 Λ 6 Π 6 V. Description of the invention (7) The Central Standards Bureau of the Ministry of Economic Affairs κχ 工 consumer cooperatives printed acid, more than -20 added acid should be a unique mechanism A single group of aerobic, poly- or di-oil or 0-fed fat tt real amount {. Base gum benzene tree two compound fat plus § such alcohol alcohol can be total anti-timer soluble, easy to add in parts ! 1 Adding alcohol diol as an agent, adding or forming a group of esters of liquid volume B can be used as an example. {£ Exciter B multiple examples. The preparation of carboxyl trapped propylene oil alone group, poly polymerization. More than quantitative control Bacterium pressure, pressure difference, single total. The source of this Mianhe and 00he's less PH chelate is not only suitable for oil, it can be prepared or due to the weight of 56% alcohol as a kind of anti-purity anti-acid charge. Example Ρ split feeling., Two two ο 20% do everything for two kinds of thin stuff than the JI into a dry object ethene 20 B, which should contain a foreign base 1 iOJ etc. I, some of them need to work together, 3 is Some of the most necessary for the formaldehyde for alcohol, alcohol must be used to neutralize this, around this use, may be used such as the extraction of ester charge. Solution I, described in category 50 and other factors, such as the agent. The agent is prepared by dissolving the alcohol and the alcohol, etc. The physical composition of the alcohol is directly prepared, I is better than the iso ester 1 and it is made up by the amount of the grade t to strengthen the amount of the compound to make the foamable substance two. d ene. Fully low, the acid-forming alcohol propionate added to the agent mixture on the proteoglycan mixture is described in the following section: if the Yuan is the sugar, the Yuming medicine is composed of a group of diacids to enable the J-source . More exemplified its pear-based hair and group and alcohol in decbii in a kind or may need to be confirmed, mountain species, it is convenient to add grade,-?, He £ »when one, / 5 must be equal, etc. / V-, Mingfang low-added vinegar Aei blend, and the alcohol used in the case of S) alcohol more OW step age hair can be used for B, A ^ ^ when the greasy substance acceptance. Two 01 three or 11 one machine is so soluble, diester acid is suitable for the use of this oil and absorption test small ethyl og propane ο into the existing. When it is equal to the amount of the v ° skin of Ethyl poplar, the equivalent amount of cr is equal to or equal to that of the substance dihydrate dihydrate W / in the case of ester alcohol. Ina examples or acid agents can be combined (please read first (Notes on the contrary will be written on this page.) This paper is used in the national B standard (CHS) T4 specification (210x297; it) 81. 7. 20,000¾ (I!) 7 203558___iii_ V. Description of the invention (8 ) Gel. The composition can be sealed in a container with LPG- to provide a spray formulation. The pharmaceutical preparations obtained in this way are not only superior in the absorption of active substances, but also safe and easy to use than any currently available antifungal preparations. Examples: The following examples and test examples further illustrate the invention. [Examples 1-4] According to the formulation shown in Table 1, benzotriazole and isopropyl myristate were mixed, and the mixture was manufactured with denatured alcohols to provide 100 ml of an external antifungal composition for external use. (Please read the precautions and fill in this page first) Blending with Zomibix Toluene III Generation Ammonia Blending --- 1/3 of 1 Example Older than the table according to the isoacid four mixing or dissolution 10 line om 10 esters into propylene to make iso, acid mixed in ten or ten or alcohol-releasing dilute alcohol-like alcohol to sex azole to squint to tolylene, tri-ester-based propylene atmosphere separately installed-order_ example comparison example shown IX The table has gotten this. i 1 Try OD to receive 10 and get 1 (use example, check the test line. The method of printing printed by the Central Standards Bureau of the Ministry of Economic Affairs, A Industrial and Consumer Cooperatives 1 ^ test example, try the implementation of the unified system Points 1-The case needs to be compared with the licorice Ιο It is released into the table. The group is finished by showing the whole fruit to absorb it. For the purpose of 11 * m 1X, each sample is used for every purpose. The cell layer is expanded and the measured layer phase has high liquid efficiency. The solution is dissolved in water and alcohol. The solution is expanded to the membrane. The 10 skins are shown in the mouse. The old fruit is over-knotted. Momentum transfer azole is similar to benzyl A, a small agent when the gas between the three generations is 81. 7. 20,000¾ (II) The paper is used in the national B country «Bi (CNS) A 4 specifications ( 2] 0 father 297 male dragon) 203558 V. Description of the invention (9) Table 1 Example Comparative Example 1 2 3 4 1 2 3 Phenyl tribenzimidazole (g) 1 1 -1. 1 1 1 1 myristic acid Isopropyl ester (g) 5 10 20 30 50-83.9 Denatured alcohols (g) 73.3 68.6 59.3 50.0 31.4 78.1 0 Mean soil SD (WS) 103.7 120.2 90.4 57.9 27.0 28.4 3.2 taxi 9 .0 soil 1.9 soil 19.1 ± 8.7 soil 3.4 ± 7.7 ± 2.0 (please read the back-up notes first and fill in the wooden page) Printed by the Employee Consumer Cooperative of the Bureau of Standards, Ministry of Economic Affairs [Examples 5-8] Air Generation Toluazole and isopropyl myristate were mixed with or without polyethylene glycol 300 or diethyl sebacate, and the mixture was diluted with isopropyl alcohol to make 100 ml. Table 2 was thus obtained. Anti-fungal external composition. [Comparative Examples 4-5] Mix air-toluidazole and isopropyl myristate, and the mixture is diluted with isopropanol to make 100ml, or air-toluidazole with isopropanol Dissolve and make 100 ml. The composition of the comparative example shown in Table 2 is thus obtained. Test Example 2 (Absorption Test) Examples 5-8 contain isopropanol as a lower alcohol and are added with polyethylene glycol 300 or sebacic acid diacetate Ethyl acetate or unused external composition. Use these paper standards to use the Zhongming National Standards (CNS) T4 specifications (2) 0X297 (¢) 81. 7. 20,000 sheets (11) 203558 V. Description of the invention (I Ο) The composition and the composition of Comparative Examples 4-5 are samples, and a collection test was conducted as described above. The results are shown in the table. 2. Table 2 Examples Comparative Examples 5 6 7 8 4 5 Chlorotribenzazole (g) 1 1 1 1 1 1 Isopropyl myristate (g) 2 5 10 15 50 Polyethylene glycol 300 (g )-10----Diethyl sebacate (g)--20---Isopropyl alcohol (g) 76.5 66.3 52.6 65.8 32.9 78.8 Mean ± SD (Wg) 42.3 92.0 35.3 30.9 10.1 20.1 ± 13.3 ± 49.3 ± 1.4 ± 3 · 2 ± 1.0 ± 5.9 (Please read the precautions before filling in this page) Packed. Line. Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs [Example 9-1 3] According to Table 3 In the formulation shown, the benzotriazole, isopropyl myristate, and crotamiton are mixed, and the mixture is diluted with denatured ethanol to 100 Bl. Thus, an antifungal composition for external use was obtained. [Comparative Examples 6-8] According to the formula shown in Table 3, the benzotriazole > isopropyl myristate and crotamiton were mixed, and the mixture was diluted with denatured alcohol to 100 81 . 7. 20,000 sheets (II) of the paper ft scale in the use of a B home «Bi (CNS) TM specifications (210X297 public) 203558 V. Description of the invention (11) ml, or a mixture of benzotriazole and gram Rotamiton, and the mixture is dissolved or mixed with denatured alcohols or isopropyl myristate to make 100〇1 | 1 丨. In this way, the composition of the comparative example shown in Table 3 was obtained. Test Example 3 (Absorption Test) Examples 9 to 13 are in addition to the essential components of the present invention, but also contain crotamiton as a dissolving agent. Using these compositions and the examples 6-8 printed by the Consumer Cooperative of the Central Bureau of Economics of the Ministry of Economic Affairs (please read the precautions first and then this page), see Table 3. Table 3 The absorption test was conducted under the same conditions as above. The results are shown in Example fcb. Comparative Example 9 10 11 12 13 6 7 8 Gasotribenzazole (g) 1 1 1 1 1 1 1 1 1 Isopropyl myristate (g) 5 10 15 20 30 50-79.4 Crotamiton (g) 5 5 5 5 5 5 5 5 Denatured alcohols (g) 70.0 65.2 60.6 56.1 46.9 28.2 74.5 0 mean soil SD 110.0 70.1 65.8 52.2 43.5 19.7 19.9 8.0 ± 19.8 soil 9.7 soil 11,0 Soil 15,6 ± 7.5 ± 4.5 ± 4.5 ± 4.8 ± 5.6 This paper size is used in the country B «Bi (CNS) T4 specification (210X297 g *) 11 81. 7. 20,000 sheets (11) Λ 6 I? 6 203558 V. Description of the invention (12) (please read the precautions and fill in this page first) It is obvious from Table 1 and Table 2 that the present invention contains the antifungal composition of the higher fatty acid ester and lower alcohols to be determined here, Shows excellent absorption kinetics. In contrast, the conventional composition cannot show sufficient absorption capacity. Even in the case where the azole drug is co-formulated with crotamiton, the composition according to the ratio of the present invention is significantly superior in absorption. [Examples 14-17] In accordance with the formulation shown in Table 4, the benzotriazole, isopropyl myristate, crotamiton, 1-menthol and lidocaine as a local anesthetic Polyethylene glycol monolaurate and / or propylene glycol were added or mixed without addition, and the mixture was diluted with denatured alcohol to 100 ml. Thus, an antifungal composition for external use was obtained. [Comparative Example 9] An external antifungal composition was prepared in the same manner as in Example 17, except that isopropyl myristate was omitted. Example 1 7 Test Example 4 (absorption test) Using the compositions of Examples 14-17 and Comparative Example 9 and the commercially available formulation A, B and C were printed by the Mongong Consumer Cooperative of the Central Bureau of Economic Development of the Ministry of Economic Affairs under the same conditions The absorption test was conducted and the results are shown in Table 4. The size of this paper is easy to use in the National Beta Standard (CHS) Τ4 specification (210X297 g; it) 12 81.7, 20,000 sheets (II) Λ 6 Η 6 203558 V. Description of the invention (13) Table 4

實施例 比較例 市售産品 14 15 16 17 9 ABC 經濟部中央標準局貞工消伢合作社印製 氯代三苯甲昧唑(g) 1 -1 1 1 1 十四酸異丙酯(g) 10 10 10 10 - 克羅他米通(g) 5 5 5 5 5 卜薄荷醇(g) 1 1 1 1 1 聚乙二醇 單十二酸(g) - 1.5 1.5 - - 丙二醇(g) - - 5 5 5 利多卡因(g) 2 2 2 2 2 變性醇類(g) 62.4 61.9 57.6 58.0 67.9 平均值土S.D, 27.6 45.3 33.1 25.3 9.1 17.4 7.4 15.4 ±3.4 土 14.5 ±3.4 士 6.5 土 6.9 土 4.1 土 2.1 土 7.2 (請先閲讀背而之注意事項^:填寫本頁) 本紙張尺度边用中a Β家標毕(CHS) Ή規格(210X297公*) 13 81. 7. 20,000ft (II) Λ 6 Π 6 203558 五、發明説明(14) 由表4明顯可見本發明的抗真菌組成物優於市售製劑 Ο [實施例1 8 - 2 2 ] 依表5所示的配方,以如先前實施例相同方式製備外 用抗真菌铀成物。 表 5 實施例 (請先閲讀背而之注意事項#填寫本頁) 18 19 20 2 1 22 經濟部中央櫺準局员工消费合作社印製 氛 代 三 苯 甲眯唑(g) 1 1 1 1 1 十 四 酸 異 丙酯(g) 5 5 10 10 10 克 羅 他 米 通U) 5 5 5 5 5 1 - 薄 荷 醇 (δ ) 1 1 1 1 1 聚 乙 二 醇 OBT 早 十 二 酸 (g ) 1 . 5 1.5 1.5 1.5 1.5 丙 二 醇 (g ) - 1 1.5 3 - 1 , 3- 丁 二 醇(g) - - - - 5 利 多 卡 因 (δ ) 2 2 2 2 2 爱 性 醇 類 (g) 66.5 65.6 6 0.3 59.6 57.8 試 驗 例5 (皮虜剌 激試驗) 利 用 實施例15, 16和18至 22所製備的組成物及 1及市售 私紙張尺度逍用中Β國家樣準(CUS) Τ4規格(210X297公址) 14 81. 7 . 20,000¾ (II) 203558 五、發明説明(15) 製劑A-G為樣本,進行皮虜剌撖試驗。 經濟部屮央榣準局貝工消费合作社印製 試 驗 方 法 * 於 F i η - Ch a π be r ( T a i s h ο P h a r m aceutical Co. ,Ltd.) 中 f 將 試 紙 浸 於 每 個 樣本中, 並 風 乾十分鐘。該試紙置於 健 康 成 人 上 臂 内 侧 0 24小時後 9 白 上臂除去試紙。 除去試 紙 1和2 4小時後, 依下列等级表記錄皮虜狀況且計 算皮嫌 刺 激 指 數 (S .I 0 結 果示於表 6〇 點 數 無 反 應 0 軽 撤 紅 斑 0.5 明 顯 紅 斑 1 紅 斑 + 浮 腫 或 丘 瘆 2 紅 斑 + 浮 腫 丘 疹或水$ 3 大 > m 死 4 皮 1» 剌 撖 指 數 (S .I .) S . I . =(在 表 現 較 大 反 應倒,移 除 後 1和24小時的總 點數)/ 試驗例之數目X 100 (請先閲讀背而之注意事項#填寫木页) 本紙張尺度逍用中Β國家樣準(CNS)T4規格(210X297公*) 81. 7. 20,000張(H) 203558 Λ 6 15 6 五、發明説明(16) 表 實施例 乙二醇含量 15 18 19 20 2 1 16 22 0 0 1 1 3 5 5 20.8 29.2 33.3 (請先閲讀背而之注意事項再填寫木頁) 經濟部中央標準局貝工消费合作社印製 市 售 産 品A 2.5 市 售 産 品B 29.2 市 售 産 品C 58.3 市 售 産 品D 17.5 市 售 産 品E 20.0 市 售 産 品F 20.0 市 售 産 品G 12.5 私紙張尺度边用中Β困家榣毕(CNS) Τ4規格(210X297公;》:) 16 81. 7 . 20,000張(II) 203558_ 五、發明説明(17) 由表6明顯可見,由本發明減少抗真菌組成物之乙二 經濟部中央櫺準局A工消t合作社印製 發此及 本 。劑 ,物解 此成溶 如組受 。菌接 低真可 降抗上 顯用學 明外藥 的的態 性性液 激全溫 剌安常 !»和之 皮收劑 致吸試 導良菌 , 優真 量具抗 的種少 物一減 合 供 由 化提 , 醇明外 免 保 確 CBE 種 1 得 獲 可 度 限 許 〇 容性 低特 最乾 至速 , 之 量覺 的感 、 物好 ΑΠ 良 : 化的果 醇著效 二粘明 乙於發 性點 活優 送加 輸附 夠的 能用 且使 收易 吸容 可及 度全 高安 為有 物具 成 , 組層 菌質 真角 抗的 之虜 明皮 發至 本遠 質 物 珠 念 及 癖 斑 花 癣 髮 如 病 虜 皮 性 菌 真 〇 在效 物功 成良 組優 本現 , 表 此上 因病 〇 菌 本紙張尺度逍用中B B家«毕(CNS)肀4規格(210X297公;it) 17 81. 7. 20,000¾ (II) (請先間讀背而之注意事項再填寫木頁)EXAMPLES Comparative Examples Commercially available products 14 15 16 17 9 ABC Printed chlorotribenzazole (g) 1 -1 1 1 1 isopropyl myristate (g) 10 10 10 10-Crotamiton (g) 5 5 5 5 5 menthol (g) 1 1 1 1 1 Polyethylene glycol monolauric acid (g)-1.5 1.5--Propylene glycol (g)- -5 5 5 Lidocaine (g) 2 2 2 2 2 Denatured alcohols (g) 62.4 61.9 57.6 58.0 67.9 Mean ± SD, 27.6 45.3 33.1 25.3 9.1 17.4 7.4 15.4 ± 3.4 ± 14.5 ± 3.4 ± 6.5 ± 6.9 ± 4.1 soil 2.1 soil 7.2 (please read the precautions ^: fill in this page) this paper is used in the standard a Β 家 标 毕 (CHS) Ή specification (210X297 public *) 13 81. 7. 20,000ft (II ) Λ 6 Π 6 203558 V. Description of the invention (14) It is clear from Table 4 that the antifungal composition of the present invention is superior to the commercially available formulations. [Examples 1 8-2 2] The formulation shown in Table 5 is as follows The antifungal uranium composition for external use was prepared in the same manner as the previous examples. Table 5 Examples (please read the back-to-back notes # fill out this page) 18 19 20 2 1 22 printed by the Ministry of Economic Affairs Central Bureau of Employee Employee's Consumer Cooperative Printed benzotriazole (g) 1 1 1 1 1 Isopropyl myristate (g) 5 5 10 10 10 Crotamiton U) 5 5 5 5 5 1-Menthol (δ) 1 1 1 1 1 Polyethylene glycol OBT Early dodecanoic acid (g) 1. 5 1.5 1.5 1.5 1.5 Propylene glycol (g)-1 1.5 3-1, 3-Butanediol (g)----5 Lidocaine (δ) 2 2 2 2 2 Love alcohols (g) 66.5 65.6 6 0.3 59.6 57.8 Test Example 5 (Piru test) Using the compositions prepared in Examples 15, 16 and 18 to 22 and 1 and commercially available private paper standards for small-scale use of the Chinese National Standard (CUS) Τ4 specifications (210X297 public address) 14 81. 7. 20,000¾ (II) 203558 V. Description of the invention (15) The preparation AG is taken as a sample, and a Piruit test is carried out. The test method printed by the Beigong Consumer Cooperative of the Ministry of Economic Affairs of the Ministry of Economic Affairs * in F i η-Ch a π be r (T aish ο P harm aceutical Co., Ltd.) f dipped the test paper in each sample, And air-dried for ten minutes. The test strip was placed on the inner side of the upper arm of a healthy adult. 0 24 hours later 9 Remove the test strip from the upper arm. After removing the test strips for 1 and 24 hours, record the skin condition according to the following grade table and calculate the skin irritation index (S.I 0. The results are shown in Table 60. There is no response. 0 erythema removal 0.5 obvious erythema 1 erythema + edema or Qiu Yan 2 erythema + puffy papules or water $ 3 large &m; dead 4 skin 1 »stab index (S.I.) S.I. = (in the performance of a large reaction down, 1 and 24 hours after removal Total points) / The number of test examples X 100 (Please read the back-end precautions #fill in the wooden page) The paper standard is used in the national standard (CNS) T4 specification (210X297) *. 81. 7. 20,000 Zhang (H) 203558 Λ 6 15 6 V. Description of the invention (16) Table Example Glycol content 15 18 19 20 2 1 16 22 0 0 1 1 3 5 5 20.8 29.2 33.3 (please read the precautions first (Fill in the wooden page again) Printed commercial product A 2.5 Commercial product B 29.2 Commercial product C 58.3 Commercial product D 17.5 Commercial product E 20.0 Commercial product F 20.0 Sale of products G 12.5 Standards for private paper use (CNS) Τ4 specifications (210X297 ;;): 16 81. 7. 20,000 sheets (II) 203558_ V. Description of invention (17) Obviously seen in Table 6 , The anti-fungal composition of the present invention is printed and distributed by the Ajiongt Cooperative of the Central Bureau of Economic Development of the Ministry of Economy, Ministry of Economic Affairs. Full-temporal liquid-excited full-temperature stimuli of Changming Foreign Medicine! »Hezhi skin-reducing agent induces good bacteria to be sucked, and the amount of anti-species and anti-species is reduced by a single supply. Ensure that CBE species 1 can be obtained to a limited extent. The low-capacity, most dry and fast, the sense of quantity and good quality ΑΠ Good: the effect of the chemical fruit alcohol is diglutinated at the hair point. Enough enough to use and make it easy to absorb and absorb. Full high safety is a good thing. The layer of veterinary true horn resists the bright skin to the distant matter. The dermatophytes are really good, and the results are good, and it is because of the disease. Use B B home «Bi (CNS) Yu 4 specifications (210X297 g; it) 17 81. 7. 20,000¾ (II) (please read the notes before filling in the wooden page)

Claims (1)

附件三 203558 第川號專利申請案 二..i 補无資枓 (於年丨月 市售品Α〜G之組成 A B C D E F G 本發明 氣代三苯甲咪唑 1 1 1 - • 眯唑条藥物 硝基米康唑 - - - 1 - - - 0.2〜5W/V % 十四酸異丙酯 69 - - 坤 - - - 高级脂肪酸酯 2〜30W/V % 乙醇 30 38 47 50 27 60 35 低级醇 45W/V %以上 甲基乙基酮 -· _ — 26 1,3-丁二醇 - 45 47 .- ? ? 聚乙二醇400 - - - 35 9 鱗 ? 水 - 06 04 - 24 30 其他基劑成份 - 8 - 14 40 7 30 硝吡咯菌素 - - - - - 05 • 6-環己基-1-羥基-4-基 - - 一 - 一 1 基-2- (1H)-吡啶_ 發癣退 - - 釋 - 2 • 南 克羅他米通 - 5 5 - • 5 一 利多卡因 - 2 - - - 够 卜薄荷醇 - - 2 - - 1 • 甘草酸 - 05 - - 05 05 - 沙夫卡因塩酸塩 - - - 02 « 水揚酸 ) - - - 2 - 或幾乎為0 ?:不明(總括含其他基劑成份) 甲 4 (210X297 公光) S03558 〇 - Η3 厂----- ' 1 — —-—. 1 第2 1 1 0£ 2 0 9號專利申請案 1么' 一 α » .( C,; 申請專利範圍修正本 .·. 一 一— —丨·》 ί (82 年 1 月 2 1 B ) 1 . — 種 外 用 抗 真 菌 醫 藥 組 成 物 t 其 包 含 0 · 2至S 重 量 /體積 % 的 咪 唑 藥 物 » 2至2 0重量/ 體 積 % 之 十 四 酸 異 丙 酯 和 至 少 45 重 量 /體積: ί的ί £级醇。 2 . 如 申 請 專 利 Mhr· 颭 圍 第 1 項 之 外 用 抗 真 菌 醫 藥 組 成 物 9 其 中 眯 唑 藥 物 為 抗 真 -*··*· 国 性 0 3 . 如 Φ 請 專 利 靶 圍 第 1 項 之 外 用 抗 真 菌 醫 藥 組 成 物 t 其 中 眯 唑 藥 物 為 具 一 或 二 或 更 多 苯 基 的 咪 唑 化 合 物 0 4 . 如 甲 請 專 m 範 圍 第 3 項 之 外 用 抗 真 菌 醫 藥 組 成 物 ) 其 中 苯 基 為 氮 原 子 所 取 代 0 5 . 如 申 請 專 利 1G 圍 弟 1 項 之 外 用 抗 真 菌 醫 藥 組 成 物 » 其 中 咪 唑 藥 物 為 選 白 由 異 康 唑 康 唑 氧 康 唑 氛 代 三 甲 苯 眯 唑 梭 康 唑 > 透 康 唑 ' 雙 風 唑 米 康 唑 及 其 塩 類 所 構 成 之 組 群 之 至 少 一 種 咪 唑 化 合 物 0 8 . 如 申 請 專 利 mi 圍 第 1 項 之 外 用 抗 真 菌 醫 藥 組 成 物 t 其 中 眯 唑 藥 物 為 氛 代 三 甲 苯 眯 唑 0 7 . 如 Φ 請 專 利 AM»· m 圍 第 1 項 之 外 用 抗 真 菌 醫 藥 組 成 物 9 其 中 低 级 醇 類 為 變 性 醇 類 0 8 . 如 申 請 專 利 範 圍 第 1 項 之 外 用 抗 真 菌 翳 藥 組 成 物 9 其 包 含 一 種 選 白 由 αο 単 十 二 酸 聚 乙 二 醇 酯 % DO 単 油 酸 聚 乙 二 醇 酯 % 十 二 基 聚 氣 化 乙 烯 酯 * 油 烯 基 聚 氣 化 乙 烯 酯 、 克 羅 他 米 通 癸 二 酸 二 乙 酯 癸 二 酸 二 異 丙 酯 > 己 二 酸 二 異 丙 酯 苯 二 酸 二 乙 、 1 - 薄 荷 醇 、 d 1 -薄荷醇、 薄荷油、 甲 4 (210X 297公寿) 1 H3 203558 油加利樹油、水揚酸甲酯及碩酸丙烯酯所構成組群之溶 解劑。 9. 如申請專利範圍笫1項之外用抗真菌醫藥組成物,其包 含一種選自由具2 0 0至6 0 0平均分子量之丙二醇、1,3-丁 二醇及聚乙二醇所構成的组群之二醇。 10. 如申請專利範圍第1項之外用抗真菌醫藥組成物,其包 含一種選自由丙三醇和山梨糖醇所構成組群之多元醇。 11. 一種包含如申請專利範圍第1至10項之任一項之外用抗 真菌醫藥組成物之製劑,其為充填於壓縮容器之泡沫製 劑、溶膠製劑、凝膠製劑或噴霧製劑的形式。\ 2 甲 4(210X297 公寿)Attachment III 203558 Patent Application No. Chuan No.2 .. I make up no capital (composition of commercially available products Α ~ G in January and October ABCDEFG of the present invention, aerobic tribenzimidazole 1 1 1-• nitrozole drug nitro Miconazole---1---0.2 ~ 5W / V% isopropyl myristate 69--Kun---Higher fatty acid ester 2 ~ 30W / V% Ethanol 30 38 47 50 27 60 35 Lower alcohol 45W / V% Methyl ethyl ketone-_ — 26 1,3-Butanediol-45 47 .-?? Polyethylene glycol 400---35 9 Scale? Water-06 04-24 30 Other bases Ingredients-8-14 40 7 30 Nitropyrrolin-----05 • 6-cyclohexyl-1-hydroxy-4-yl--mono-mono 1 yl-2- (1H) -pyridine --Release-2 • South Crotamide-5 5-• 5 Lidocaine-2---Methyl menthol--2--1 • Glycyrrhizic acid-05--05 05-Shafka Due to acidic acid---02 «salicylic acid)---2-or almost 0?: Unknown (including other base ingredients in total) A 4 (210X297 public light) S03558 〇- Η3 Factory ----- ' 1 — —-—. 1 2 1 1 0 £ 2 0 9 Patent Application No. 1 '1α ». (C ,; Amendments to the scope of the patent application ..... 1 — — 丨》 ί (January 2 1 82) 1. — An antifungal pharmaceutical composition for external use t containing 0 · 2 to S weight / volume% imidazole drug »2 to 20 weight / vol% isopropyl myristate and at least 45 weight / volume: ί £ 2. Alcohol grade 2. Anti-fungal pharmaceutical composition for applications other than the patented Mhr · Section 1 Item 9 in which the azole drug is anti-true · * ·· * · National 0 3. For example, Φ Please patent the target item 1 External antifungal pharmaceutical composition t where the azole compound is an imidazole compound having one or two or more phenyl groups 0 4. For example, please use the antifungal pharmaceutical composition outside the scope of item 3) where phenyl is nitrogen The atom is replaced by 0 5. For example, if the patent application 1G is applied for 1 item, the anti-fungal medicine group物 »Among which the imidazole drug is at least one imidazole selected from the group consisting of isoconazole, conazole, oxyconazole, benzotriazole, and conazole; Compound 0 8. For anti-fungal medicinal composition other than the first item in the application of mi circumstance t where the azole drug is benzotriazole 0 7. For example Φ please patent AM »· m for anti-fungal excluding item 1 Pharmaceutical composition 9 wherein the lower alcohol is a denatured alcohol 0 8. The anti-fungal pancreatic medicine composition 9 is used outside the scope of the patent application. It contains a selection of αο polyethylene glycol ester of dodecanoic acid% DO 単Polyethylene glycol oleate% Dodecyl polygasified vinyl ester * Olefinyl polygasified vinyl ester, Crotamiton diethyl sebacate diisopropyl sebacate > Adipate di Isopropyl diphthalate, 1-Thin alcohol, d 1 -menthol, peppermint oil, A 4 (210X 297 Kg) 1 H3 203558 Solvent of the group consisting of oil kali tree oil, methyl salicylate and allyl propionate. 9. If the anti-fungal pharmaceutical composition is used outside of the first item of the patent application, it contains a composition selected from the group consisting of propylene glycol having an average molecular weight of 200 to 600, 1,3-butanediol and polyethylene glycol. Group of diols. 10. If the antifungal pharmaceutical composition is used outside the scope of patent application item 1, it contains a polyol selected from the group consisting of glycerin and sorbitol. 11. A preparation containing an antifungal pharmaceutical composition other than any one of claims 1 to 10 in the form of a foam preparation, a sol preparation, a gel preparation, or a spray preparation filled in a compressed container. \ 2 A 4 (210X297 Gongshou)
TW81105209A 1991-07-03 1992-07-01 Antifungal composition for external application TW203558B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19077891 1991-07-03

Publications (1)

Publication Number Publication Date
TW203558B true TW203558B (en) 1993-04-11

Family

ID=16263577

Family Applications (1)

Application Number Title Priority Date Filing Date
TW81105209A TW203558B (en) 1991-07-03 1992-07-01 Antifungal composition for external application

Country Status (3)

Country Link
JP (1) JP2555555B2 (en)
CN (1) CN1068736A (en)
TW (1) TW203558B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07267862A (en) * 1994-03-29 1995-10-17 Sekisui Chem Co Ltd Transdermal plaster
JPH07309755A (en) * 1994-05-20 1995-11-28 Nichiban Co Ltd Cataplasm of antifungal agent
GB9500983D0 (en) * 1995-01-19 1995-03-08 Agrevo Uk Ltd Pesticidal compositions
GB9620248D0 (en) * 1996-09-26 1996-11-13 Scotia Holdings Plc Esters of unsaturated fatty acids
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
DE19921794A1 (en) * 1999-05-11 2000-11-23 Hexal Ag New pharmaceutical composition
JP5062995B2 (en) * 2004-12-20 2012-10-31 ロート製薬株式会社 Preventive and therapeutic agent for vaginal candidiasis or vulvar candidiasis
WO2006098353A1 (en) * 2005-03-15 2006-09-21 Kyowa Hakko Kogyo Co., Ltd. External preparation
JP4974526B2 (en) * 2005-12-29 2012-07-11 ロート製薬株式会社 Composition for preventing or treating candidiasis
WO2007102243A1 (en) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2025337B1 (en) 2006-03-08 2014-09-10 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
RU2423128C2 (en) 2006-03-08 2011-07-10 Нихон Нохияку Ко., Лтд. Pharmaceutical composition for external application
WO2009031642A1 (en) 2007-09-05 2009-03-12 Pola Pharma Inc. Pharmaceutical composition
WO2009031643A1 (en) 2007-09-05 2009-03-12 Pola Pharma Inc. Antifungal composition
EP2191828B1 (en) 2007-09-05 2016-08-10 Pola Pharma Inc. Antifungal pharmaceutical composition
JP5688405B2 (en) 2009-04-09 2015-03-25 株式会社ポーラファルマ Antifungal pharmaceutical composition
JP5688406B2 (en) 2009-04-09 2015-03-25 株式会社ポーラファルマ Antifungal pharmaceutical composition
WO2011024620A1 (en) 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP6377423B2 (en) * 2014-06-17 2018-08-22 ロート製薬株式会社 Composition for external use
TWI834808B (en) * 2019-02-19 2024-03-11 西班牙商薩爾瓦特實驗室有限公司 Single-dose packaged clotrimazole liquid composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045914A1 (en) * 1980-12-05 1982-07-22 Bayer Ag, 5090 Leverkusen ANTIMYCOTIC AGENTS WITH HIGH ACTIVE SUBSTANCE RELEASE IN THE FORM OF ELASTIC LIQUID PLASTERS
DE3045915A1 (en) * 1980-12-05 1982-07-08 Bayer Ag, 5090 Leverkusen ANTIMYCOTIC AGENTS WITH HIGH ACTIVE SUBSTANCE RELEASE IN THE FORM OF ELASTIC LIQUID PLASTERS
DE3106635A1 (en) * 1981-02-23 1982-09-09 Bayer Ag ANTIMYCOTIC AGENT WITH HIGH ACTIVE SUBSTANCE RELEASE IN THE FORM OF PEN
DE3311700A1 (en) * 1983-03-30 1984-10-04 Bayer Ag ANTIMYCOTIC AGENTS WITH HIGH ACTIVE SUBSTANCE RELEASE IN THE FORM OF SOLUTION AND SPRAY

Also Published As

Publication number Publication date
JPH05306223A (en) 1993-11-19
CN1068736A (en) 1993-02-10
JP2555555B2 (en) 1996-11-20

Similar Documents

Publication Publication Date Title
TW203558B (en) Antifungal composition for external application
Kar et al. Current developments in excipient science: implication of quantitative selection of each excipient in product development
Kulkarni et al. Essential chemistry for formulators of semisolid and liquid dosages
US8703105B2 (en) Oleaginous pharmaceutical and cosmetic foam
DK2494959T3 (en) Foam Bart dicarboxylsyrebærestof and pharmaceutical compositions thereof
Rai et al. Development of cellulosic polymer based gel of novel ternary mixture of miconazole nitrate for buccal delivery
CN101511339B (en) Anhydrous multiphase gel system
Tamarkin Foam: a unique delivery vehicle for topically applied formulations
El-Badry et al. Comparative topical delivery of antifungal drug croconazole using liposome and micro-emulsion-based gel formulations
Parashar et al. Formulation and evaluation of gel containing miconazole nitrate an antifungal agent
Charoo et al. Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil
US8679470B2 (en) Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications
TW200815045A (en) Pharmaceutical compositions of ropinirole and methods of use thereof
JP2008540508A (en) Foaming vehicle and pharmaceutical composition thereof
CN106456543A (en) Non-rinse chemical mousse containing benzoyl peroxide
Gennari et al. Medicated foams and film forming dosage forms as tools to improve the thermodynamic activity of drugs to be administered through the skin
CN106620445B (en) Skin-care microemulsion gel and preparation method thereof
US8647671B2 (en) Compositions and methods for the treatment of skin diseases
Yasir Siddique et al. Microemulsified gel formulations for topical delivery of clotrimazole: structural and in vitro evaluation
CN102112151A (en) Microneedle device and method for increasing the response of japanese encephalitis virus antigen with the microneedle device
WO2004006960A1 (en) Transdermal absorption preparation
AU2009273211B2 (en) Transdermal pharmaceutical compositions comprising danazol
JP2018532773A (en) Rinse-free chemical foam containing brimonidine and its use in the treatment of rosacea
Sangale et al. Organogel: A novel approach for transdermal drug delivery system
CN101224298B (en) Propofol compounds